Abstract 675P
Background
JSKN003 is a novel HER2-directed antibody-drug conjugate (ADC) conjugated to a topoisomerase I inhibitor via a dibenzocyclooctyne tetrapeptide linker on the glycans of a humanized bispecific antibody. JSKN003-101 and JSKN003-102 is dose escalation and expansion studies in Australian and Chinese patients (pts) with metastatic solid tumors.
Methods
This is pooled analysis from pts enrolled in JSKN003-101 and JSKN003-102 with histologically documented HER2-positive (IHC 3+) solid tumors who failed prior systemic therapies, received JSKN003 monotherapy intravenously Q3W. The objectives were safety and efficacy of JSKN-003.
Results
As of 15th Mar 2024, 24 pts (7 CRC, 5 GC, 3 ESCA, 2 OC, 2 BTC, and 5 others) were enrolled and JSKN003 dosed across 6 dose levels, including 2.1 mg/kg, 4.2 mg/kg, 5.2 mg/kg, 6.3 mg/kg, 7.3 mg/kg and 8.4 mg/kg. 10 pts (41.7%) received ≥ 3 prior lines of therapy,6 pts(25%) received anti-HER2 ADC. The median duration of treatment was 13.9 (range,9.4,19.8) weeks, and 20 pts (83.3%) remained on treatment. Treatment-related adverse events (TRAEs) occurred in 23 pts (95.8%), and the mostly common grade 1 and 2 TRAEs were diarrhea (62.5%) and nausea (58.3%), infusion related reaction (29.2%), fatigue (25.0%).5 pts (20.8%) experienced grade ≥3 TRAEs, were neutropenia (8.3%), vomiting (4.2%), fatigue (4.2%) and abdominal discomfort (4.2%). 2 pts had interstitial lung disease, grade 2 (occurred in 6.3 mg/kg), both recovered thereafter. No TRAE led to death or discontinuation. 22 pts with tumor assessment, the ORR and DCR were 72.7% (95%CI: 49.8, 89.3) and 95.5% (95%CI: 77.2, 99.9). 5 pts who received prior anti-HER2 ADC, the ORR was 80% and median DOR was more than 30 weeks.
Conclusions
JSKN003 was well tolerated with encouraging preliminary antitumor activity in heavily pretreated pts with advanced HER2-positive (IHC ≥ 3+) solid tumors, which support further clinical development.
Clinical trial identification
NCT05494918; NCT05744427.
Editorial acknowledgement
Legal entity responsible for the study
Alphamab Oncology.
Funding
Alphamab Oncology.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
630P - Debio 0123 + carboplatin (CP) for patients (pts) with advanced solid tumors: Safety, preliminary efficacy and determination of recommended phase II dose (RP2D)
Presenter: Hans Gelderblom
Session: Poster session 01
631P - Phase Ib expansion study of CX-5461 in patients with solid tumours and BRCA2 and/or PALB2 mutation
Presenter: Pamela Soberanis Pina
Session: Poster session 01
632P - Results from the first-in-human study of ATR inhibitor, IMP9064 monotherapy dose escalation in patients with advanced solid tumors
Presenter: Chia-Chi Lin
Session: Poster session 01
633P - First-in-human dose-escalation study of basroparib (STP1002) in patients with advanced-stage solid tumors
Presenter: Christopher Lieu
Session: Poster session 01
634P - First results from phase I/II study of CTS2190, a novel small-molecule inhibitor of type I PRMTs, in patients with advanced solid tumors
Presenter: Xiangdong Cheng
Session: Poster session 01
635P - The phase I dose-escalation study of TSN084, a multi-kinase inhibitor, in patients with advanced malignant tumors
Presenter: Jie Wang
Session: Poster session 01
636P - Tucatinib and trastuzumab in advanced cancers with HER2 mutations or amplification: A molecular screening and therapeutics (MoST) program substudy
Presenter: Benjamin Kong
Session: Poster session 01
637P - AC699, a novel chimeric estrogen receptor degrader, in a phase I study in breast cancer
Presenter: Erika Hamilton
Session: Poster session 01
638P - Final results of IMPACT 2, a randomized study evaluating molecular profiling and targeted agents in metastatic cancer at MD Anderson Cancer Center
Presenter: Apostolia Maria Tsimberidou
Session: Poster session 01
639P - Serial ctDNA profiling as a catalyst for tailored therapeutics in advanced cancer: Analysis of two precision medicine studies
Presenter: Sophie Cousin
Session: Poster session 01